What drugs does MARKSANS PHARMA make?

MARKSANS PHARMA has 17 FDA-approved drugs.

What therapeutic areas does MARKSANS PHARMA focus on?

MARKSANS PHARMA focuses primarily on Immunology and Infectious Disease and 1 other therapeutic areas.

← Back

Data updated: Jun 28, 2026

MARKSANS PHARMA

Generics

Immunology Infectious Disease Cardiovascular

MARKSANS PHARMA is a generic drug manufacturer focused on Immunology, Infectious Disease, Cardiovascular.

2002

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

MARKSANS PHARMA's Key Drugs

MARKSANS PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MARKSANS PHARMA's Recent FDA Approvals

MARKSANS PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

MARKSANS PHARMA's Therapeutic Areas

MARKSANS PHARMA's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 25%

1 drugs

Infectious Disease 25%

1 drugs

Cardiovascular 25%

1 drugs

Gastroenterology 25%

1 drugs

MARKSANS PHARMA's Top Competitors

MARKSANS PHARMA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Sanofi, and WARNER CHILCOTT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma

Immunology, Infectious Disease, Gastroenterology

Sanofi big-pharma

Infectious Disease, Immunology, Cardiovascular

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Infectious Disease, Immunology

Bristol-Myers Squibb big-pharma

Immunology, Infectious Disease, Gastroenterology

BAUSCH specialty

Immunology, Cardiovascular, Gastroenterology